Effects of Fluticasone Propionate on Klebsiella pneumoniae and Gram-Negative Bacteria Associated with Chronic Airway Disease
ABSTRACT Inhaled corticosteroids (ICS) are commonly prescribed first-line treatments for asthma and chronic obstructive pulmonary disease (COPD). Recent evidence has shown that ICS use is associated with changes in the airway microbiome, which may impact clinical outcomes such as potential increased...
Main Authors: | Lesa A. Begley, Kristopher Opron, Guowu Bian, Ariangela J. Kozik, Cai Liu, Jeremy Felton, Bo Wen, Duxin Sun, Yvonne J. Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2022-12-01
|
Series: | mSphere |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/msphere.00377-22 |
Similar Items
-
Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies
by: Lodise TP, et al.
Published: (2020-11-01) -
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
by: Beeh KM, et al.
Published: (2016-02-01) -
Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
by: Sun Hye Shin, et al.
Published: (2022-05-01) -
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
by: Price DB, et al.
Published: (2022-02-01) -
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
by: Price DB, et al.
Published: (2022-03-01)